Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
ARIPIPRAZOLE (UNII: 82VFR53I78) (ARIPIPRAZOLE - UNII:82VFR53I78)
Trigen Laboratories, LLC
ARIPIPRAZOLE
ARIPIPRAZOLE 10 mg
ORAL
PRESCRIPTION DRUG
Aripiprazole Orally Disintegrating Tablets, USP are indicated for the treatment of: •Schizophrenia [see CLINICAL STUDIES (14.1)] Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. Aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis [see ADVERSE REACTIONS (6.2)]. Teratogenic Effects Pregnancy Category C: Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ . Risk Summary Neonates exposed
Aripiprazole Orally Disintegrating Tablets, USP are round tablets with markings on one side and plain on other side. Aripiprazole Orally Disintegrating Tablet is available in the strengths and packages listed in Table 33. Table 33: Aripiprazole Orally Disintegrating Tablets, USP Presentations Store at 20° to 25°C (68° to 77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature].
Abbreviated New Drug Application
ARIPIPRAZOLE - ARIPIPRAZOLE TABLET, ORALLY DISINTEGRATING Trigen Laboratories, LLC ---------- MEDICATION GUIDE Aripiprazole (AR-i-PIP-ra-zole ) Orally Disintegrating Tablets, USP What is the most important information I should know about aripiprazole? (For other side effects, also see “What are the possible side effects of aripiprazole?”). Serious side effects may happen when you take aripiprazole, including: • Increased risk of death in elderly patients with dementia-related psychosis: Medicines like aripiprazole can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Aripiprazole is not approved for the treatment of patients with dementia- related psychosis. • Risk of suicidal thoughts or actions: Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions: 1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called Manic-depressive illness) or suicidal thoughts or actions. 3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. • Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms. Call a healthcare provider right away Les hele dokumentet
ARIPIPRAZOLE - ARIPIPRAZOLE TABLET, ORALLY DISINTEGRATING TRIGEN LABORATORIES, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ARIPIPRAZOLE ORALLY DISINTEGRATING TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ARIPIPRAZOLE ORALLY DISINTEGRATING TABLETS. ARIPIPRAZOLE ORALLY DISINTEGRATING TABLETS INITIAL U.S. APPROVAL: 2002 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ •ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. ARIPIPRAZOLE IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (5.1) •INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS TAKING ANTIDEPRESSANTS. MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS. (5.3) RECENT MAJOR CHANGES Warnings and Precautions, Pathological Gambling and Other Compulsive Behaviors (5.8) 8/2016 Warnings and Precautions, Falls (5.10) 2/2017 INDICATIONS AND USAGE Aripiprazole is an atypical antipsychotic indicated as oral formulations for : (1) Schizophrenia (14.1) DOSAGE AND ADMINISTRATION Initial Dose Recommended DoseMaximum Dose Schizophrenia – adults (2.1) 10 to 15 mg /day 10 to 15 mg /day 30 mg /day Schizophrenia – adolescents (2.1) 2 mg /day 10 mg /day 30 mg /day •Oral formulations: Administer once daily without regard to meals (2) •Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) (2) DOSAGE FORMS AND STRENGTHS Orally Disintegrating Tablets: 10 mg and 15 mg (3) CONTRAINDICATIONS Known hypersensitivity to aripiprazole (4) WARNINGS AND PRECAUTIONS _Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis:_ Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities) Les hele dokumentet